Verification Methods for 198 Common Raw Materials Using a Handheld Raman Spectrometer - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Verification Methods for 198 Common Raw Materials Using a Handheld Raman Spectrometer
Using handheld Raman spectroscopy, methods were developed and evaluated for 198 substances widely used as raw materials.

Pharmaceutical Technology
Volume 33, Issue 10, pp. 72-82


Figure 1: TruScan handheld material identity verification system based on Raman spectroscopic technology.
This study used five handheld material-identity verification systems (TruScan, Ahura Scientific, Wilmington, MA, see Figure 1). These instruments use Raman spectroscopy as the analytical technique and contain a 785-nm NIR external cavity-stabilized, thermoelectrically cooled laser as the light source. The laser typically operates at 300 mW output and automatically adjusts if necessary to avoid detector saturation. These instruments also include a single-pass dispersive spectrometer, a cooled CCD detector array, and dielectric edge filters for Rayleigh rejection. Each instrument has an integrated barcode reader for selecting methods and capturing sample lot/batch/other identifiers. Table I shows specifications for the TruScan Raman material identity verification system.

Acquiring a spectrum is facilitated by using an auto-acquisition mode that monitors incoming data in real time and automatically adjusts the control settings (e.g., laser power, exposure time, number of exposures) such that spectra of comparable statistical resolving power are achieved from one measurement to the next. This adaptive approach to spectroscopy ensures consistent statistical performance of the instrument and embedded decision algorithms regardless of operating conditions.

Four of the instruments (hereafter called reference devices) were used to acquire reference spectra for the 198 materials included in this study (see sidebar, "Materials tested"). To obtain the reference spectra, a reference sample of each material contained in a borosilicate glass vial (Kimble Glass, Vineland, NJ) was placed at the correct distance from the device's laser aperture using a vial-holder accessory. All data acquisition was performed in auto-mode. For test spectra, most analyses are complete in less than one minute. Reference-grade spectra used for method development are also generated using an auto-mode; however, these spectra have higher standards for signal-to-noise ratio than a standard test spectrum and therefore require a longer data acquisition time. Most auto-mode reference spectra are acquired in less than 30 min. The scans that did not auto-terminate within 45 min were manually stopped at 45 min to prevent photobleaching.

Reference spectra can be transferred between TruScan devices using a compact flash card or a standard web browser that addresses the device via a TCP/IP connection. Using these approaches, the reference spectra were transferred from the four reference devices to the test device. Once all of the reference spectra had been transferred to the test device, the TCP/IP utility WebAdmin was used to generate a new method for each of the 198 materials using only one reference spectrum for each method. In the context of the TruScan device, methods are analytical tasks based on stored reference spectra that the instrument's software executes to determine whether a material's identity can be verified.

To challenge the methods, a test sample of each material was placed in a borosilicate glass vial, and the vial was inserted into the test device's vial holder. For each test sample, a spectrum was acquired using auto-mode. The onboard processor then evaluated the spectrum acquired for each test material against the method developed for that material, and also against all the methods created for the rest of the 198 materials, for a total of 39,204 evaluations of test spectra against methods. In addition to the pass and fail results normally presented by the test device, the p-value was recorded for each test sample–method evaluation pair.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here